Viridian Therapeutics, Inc.
VRDNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeViridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company carries a $2.53B market cap, placing it firmly in the mid-cap category. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
Market Cap
$2.53B
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-8.12
EPS (TTM)
$-3.39
EPS (Fwd)
$-2.75
ROE
-65.7%
ROA
-30.2%
Cash
$981.5M
Total Debt
$244.7M
Free CF
-$275.5M
52W Change
-0.8%
Annual Financials
Cash vs Debt
Where VRDN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VRDN finished 7.66% above its 150-day moving average ($19.32) and 5.92% below its 200-day moving average ($22.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRDN overbought or oversold?
At the October 20, 2026 close, VRDN's RSI(14) was 54.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $981.5M in cash comfortably exceeding the $244.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$275.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -65.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.8M to $70.8M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VRDN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.